TheStreet’s Jim Cramer is asked for advice on Mannkind, which has doubled in value after an FDA panel recommended approval of its insulin drug Afreeza, but has dropped off after the FDA delayed its decision. Cramer says Visa is getting “clubbed” and he needs to look into the credit card companies a little more, but FireEye is a “high-flyer.” Finally, Cramer says he is unsure if Linn Energy’s recently-declared dividend is safe. Send your Twitter questions to #CramerQ on Monday mornings.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
